Health Care • Biotechnology: Pharmaceutical Preparations
$37.62 ▲ +0.21
(+0.56%)
MKT CAP: $3.62B • VOL: 2.38M
52W L $33 52W H $73
XENE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.04B | $782.0M | $599.4M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$373.1M | -$279.3M | -$214.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$345.9M | -$234.3M | -$182.4M |
| EBITDA (Normalized) | -$372.4M | -$276.8M | -$214.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$279.1M | -$181.4M | -$151.1M |
| Capital Expenditures (CapEx) | $799.0K | $3.1M | $0 |
| Free Cash Flow (FCF) | -$279.9M | -$184.5M | -$151.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -34.9% | -14.0% |
| Cash & Short-Term Equivalents | $199.2M | $142.7M | — |
| Total Debt (Short + Long Term) | $23.1M | $19.5M | $467.9M |
| Total Stockholders' Equity | $581.8M | $754.9M | $959.7M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XENE.